On March 12, 2025, the company received in-principle approvals from NSE and BSE for the issuance and allotment of 18,607,969 equity shares on a preferential basis for consideration other than cash in order to shore-up its equity and support its expansion initiatives. The approvals shall be valid, subject to the company complying with several important conditions, including filing a listing application post-allotment in time and obtaining the relevant statutory approvals from bodies such as the Securities and Exchange Board of India (SEBI), Reserve Bank of India (RBI), and Ministry of Corporate Affairs (MCA), among others, while complying with all prevailing guidelines and regulations. To this end, the issue also requires approval from the Competition Commission of India (CCI). The company has also been advised to strengthen internal controls for the trades executed by the proposed allottees so as to prevent any instance of non-compliance with SEBI regulations. The company would also seek undertakings from the allottees not to carry out intraday trading or sale of shares of the company until the allotment date. These developments portray Aster DM Healthcare's commitment towards regulatory compliance in its growth endeavors
Source: Financial News Network.